Henshaw Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Henshaw Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,592	Closed	-$928K	–	351
2020 Q4	$928K	Sell	1,592 -726	-31%	-$413K	0.07%	107
2020 Q3	$1.19M	Hold	2,318	–	–	0.09%	84
2020 Q2	$1.05M	Sell	2,318 -1,375	-37%	-$607K	0.09%	84
2020 Q1	$1.29M	Hold	3,693	–	–	0.13%	63
2019 Q4	$1.37M	Hold	3,693	–	–	0.11%	83
2019 Q3	$1.23M	Hold	3,693	–	–	0.1%	78
2019 Q2	$1.15M	Hold	3,693	–	–	0.1%	85
2019 Q1	$1.13M	Hold	3,693	–	–	0.1%	83
2018 Q4	$858K	Sell	3,693 -2,934	-44%	-$787K	0.08%	98
2018 Q3	$2.07M	Hold	6,627	–	–	0.17%	63
2018 Q2	$1.91M	Hold	6,627	–	–	0.17%	64
2018 Q1	$1.66M	Hold	6,627	–	–	0.15%	70
2017 Q4	$1.58M	Sell	6,627 -1,243	-16%	-$301K	0.15%	72
2017 Q3	$1.75M	Hold	7,870	–	–	0.18%	59
2017 Q2	$1.78M	Hold	7,870	–	–	0.19%	61
2017 Q1	$1.57M	Hold	7,870	–	–	0.17%	64
2016 Q4	$1.43M	Hold	7,870	–	–	0.17%	65
2016 Q3	$1.29M	Hold	7,870	–	–	0.16%	63
2016 Q2	$1.13M	Hold	7,870	–	–	0.15%	73
2016 Q1	$1.08M	Buy	+7,870	New	+$1.03M	0.14%	72

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Henshaw Capital's BIO Position: Q1 2021 in Review

Henshaw Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2021, closing a stake of 1,592 shares — an estimated $928K sold.

Henshaw Capital first reported a position in BIO in Q1 2016 and held it in 20 quarters. The position peaked at $2.07M in Q3 2018. 491 funds tracked by Wall St. Rank hold BIO as of Q1 2021.

Henshaw Capital reported no remaining Bio-Rad Laboratories Class A position as of Q1 2021 after selling out during the quarter.
Henshaw Capital sold 1,592 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $928K.
Henshaw Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2016 and held it in 20 quarters.
Henshaw Capital's Bio-Rad Laboratories Class A position peaked at $2.07M in Q3 2018.
491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.

Based on Henshaw Capital's 13F filing for Q1 2021, filed 28 May 2026.